Search for content, post, videos

Vicore Pharma approved for listing

Nasdaq Stockholm’s listing committee has approved Vicore Pharma Holding application to be listed on Nasdaq Stockholm’s main market, subject to customary conditions.

The last day of trading on Nasdaq First North Growth Market is expected to be Thursday September 26, 2019 and the first day of trading on Nasdaq Stockholm is expected to be Friday September 27, 2019.

The shares will be traded in the Small Cap segment under the same ticker (VICO) and with the same ISIN code (SE0007577895) as before. No new shares will be issued in connection with the listing. Shareholders of Vicore do not need to take any action in connection with the listing on Nasdaq Stockholm or the delisting from Nasdaq First North Growth Market.

“The up-listing to Nasdaq Stockholm’s main market is a significant step in our long-term plan do develop Vicore. The aim is to further increase the attractiveness of the Vicore share through increased liquidity as the addressable investor base grows significantly”, says Carl-Johan Dalsgaard, CEO of Vicore Pharma.